Review ArticleClinical Review

Women at High Risk for Breast Cancer—What the Primary Care Provider Needs to Know

Nelia Afonso
The Journal of the American Board of Family Medicine January 2009, 22 (1) 43-50; DOI: https://doi.org/10.3122/jabfm.2009.01.070188

References

  1. ↵
    Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mamograms (1989–1997) and papanicolaou tests (1991–1997)—Behavioral Risk Factor Surveillance System. MMWR CDC Surveill Summ 1999; 48: 1–22.
    OpenUrlPubMed
  2. ↵
    Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276–99.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005; 293: 1245–56.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2003. Bethesda (MD): National Cancer Institute; 2006.
  5. ↵
    US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143: 355–61.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early- onset breast cancer: Implications for risk prediction. Cancer 1994; 73: 643–51.
    OpenUrlCrossRefPubMedWeb of Science
  7. Palomaki GE, McClain MR, Steinort K, et al. Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med 2006; 8: 161–8.
    OpenUrlPubMedWeb of Science
  8. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–30.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc 2003; 78: 708–15.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005; 143: 446–57.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Urban J. Bilaterality of cancer of the breast: Biopsy of the opposite breast. Cancer 1967; 20: 1867–70.
    OpenUrlCrossRefPubMed
  13. ↵
    Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978; 2: 225–51.
    OpenUrlPubMedWeb of Science
  14. ↵
    Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430–41.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Agency for Healthcare Research and Quality. Diagnosis and Management of Specific Breast Abnormalities. AHRQ Publication No. 01-E045, April 2001. Available from: http://www.ahrq.gov/clinic/epcsums/abnorsum.htm. Accessed 26 June 2008.
  16. ↵
    McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159–69.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227–36.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–86.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999; 91: 1541–8.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358–66.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996; 14: 1730–6.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002; 20: 2701–12.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Heywang-Kobrunner SH, Bick U, Bradley WG Jr, et al. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 2001; 11: 531–46.
    OpenUrlCrossRefPubMedWeb of Science
  24. Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187: 493–501.
    OpenUrlPubMedWeb of Science
  25. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193: 777–81.
    OpenUrlPubMedWeb of Science
  26. Liu PF, Debatin JF, Caduff RF, et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998; 71: 501–9.
    OpenUrlAbstract
  27. Lehman CD. Role of MRI in screening women at high risk for breast cancer. J Magn Reson Imaging 2006; 24: 964–70.
    OpenUrlCrossRefPubMed
  28. ↵
    Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75–89.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA 2003; 290: 1331–6.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296: 193–201.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279: 535–40.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Tjonneland A, Christensen J, Olsen A, et al. Folate intake, alcohol and risk of breast cancer among postmenopausal women in Denmark. Eur J Clin Nutr 2006; 60: 280–6.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Baglietto L, English DR, Gertig DM, Hopper JL, Giles GG. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. BMJ 2005; 331: 807.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295: 629–42.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    Garland CF, Garland FC, Gorham E, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96: 252–61.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–88.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8: 580–5.
    OpenUrlPubMedWeb of Science
  38. ↵
    Vogel VG, Constantino JP, Wicherham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–41. Epub 2006 June 5.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131–9.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Cuzick J. Aromatase inhibitors in prevention–data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003; 163: 96–103, discussion 264–6.
    OpenUrlPubMed
  41. ↵
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84.
    OpenUrlCrossRefPubMedWeb of Science
  42. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633–7.
    OpenUrlAbstract/FREE Full Text
  43. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159–64.
    OpenUrlCrossRefPubMedWeb of Science
  44. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 1055–62.
    OpenUrlAbstract/FREE Full Text
  45. Geiger AM, Yu O, Herrinton LJ, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med 2005; 165: 516–20.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: Position Statement on Prophylactic Mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol 2007; 14: 2425–7. Epub 2007 June 28.
    OpenUrlCrossRefPubMed
  47. ↵
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 1609–15.
    OpenUrlCrossRefPubMedWeb of Science
  48. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 1616–22.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 2007; 19: 27–30.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section